BioXcel Therapeutics, a biopharmaceutical company, is making waves with its AI-driven approach to drug discovery, focusing on neuroscience. Their lead product, IGALMI, targets severe agitation in schizophrenia and bipolar disorder patients. A recent trial success has led to a submission for FDA approval for at-home use. The company is also moving forward with a program to address agitation in Alzheimer’s patients. Financially, BioXcel saw $98,000 in net revenue in the third quarter, with increased R&D spending and a net loss. Wall Street analysts have a “Moderate Buy” rating on BTAI stock, with a high price estimate suggesting significant upside potential.

Read more at Barchart: 1 Top Penny Stock to Watch Now